All news
Press release | March 5, 2013

Delphi advised in connection with Immunicum AB (publ) issues new shares before listing on NASDAQ OMX First North

Immunicum AB (publ) is a Swedish company based in Gothenburg, which develops therapeutic cancer vaccines. Immunicum has created patented methods to activate the body’s own immune system to attack cancer cells, including metastatic cancer with the goal of improving both survival and quality of life. The main product INTUVAX ™ is based on white blood cells taken from healthy blood donors, known as allogeneic dendritic cells. The dendritic cell’s role has proven to be so central to the body’s immune system so its discoverer, in 2011, was awarded the Nobel Prize in medicine. Immunicum’s unique platform technologies can basically be adapted to all forms of cancer.

 

Immunicum is now carrying out a new share issue of up to 21.4 million SEK, with distribution to the public for future listing of the Company’s shares on NASDAQ OMX First North (assuming the free float requirement, etc. is achieved). The new share issue is made in order to strengthen the company’s financial position before the completion of the company’s phase I/II study in renal cancer, and to initiate a study on liver cancer.

G&W Fondkommission is acting as financial advisor to Immunicum in connection with the transaction and the imminent listing on NASDAQ OMX First North. Delphi has provided legal advice regarding the transaction. Delphi’s team was led by partner Mats Dahlberg and associate Gunnar Svedberg.

 

Previous post

Next post